{
  "title": "Why Health Care's Future Is All About Value",
  "description": "Health care is projected to make up nearly forty percent of the US federal budget by 2025. In an effort to slow down cost increases, some in the industry have begun to explore value-based contracts, potentially transforming the industry's economics. Jami Rubin and Robert P. Jones of Goldman Sachs Research discuss how placing an emphasis on patient outcomes - instead of volumes of medications or services sold - could impact investors, companies and consumers.\n\n\nThis podcast was recorded on July 12, 2017.\n\n\nAll price references and market forecasts correspond to the date of this recording.\n\n\nThis podcast should not be copied, distributed, published or reproduced, in whole or in part. The information contained in this podcast does not constitute research or a recommendation from any Goldman Sachs entity to the listener. Neither Goldman Sachs nor any of its affiliates makes any representation or warranty, as to the accuracy or completeness of the statements or any information contained in this podcast and any liability therefor (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed. The views expressed in this podcast are not necessarily those of Goldman Sachs, and Goldman Sachs is not providing any financial, economic, legal, accounting or tax advice or recommendations in this podcast.  In addition, the receipt of this podcast by any listener is not to be taken as constituting the giving of investment advice by Goldman Sachs to that listener, nor to constitute such person a client of any Goldman Sachs entity.\n\n\nCopyright 2017 Goldman Sachs. All rights reserved.",
  "pubDate": "Thu, 20 Jul 2017 21:30:00 -0000",
  "itunes:episodeType": "full",
  "itunes:author": "Goldman Sachs",
  "itunes:image": "",
  "itunes:subtitle": "A conversation on the US health care system",
  "itunes:summary": "Health care is projected to make up nearly forty percent of the US federal budget by 2025. In an effort to slow down cost increases, some in the industry have begun to explore value-based contracts, potentially transforming the industry's economics. Jami Rubin and Robert P. Jones of Goldman Sachs Research discuss how placing an emphasis on patient outcomes - instead of volumes of medications or services sold - could impact investors, companies and consumers.\n\n\nThis podcast was recorded on July 12, 2017.\n\n\nAll price references and market forecasts correspond to the date of this recording.\n\n\nThis podcast should not be copied, distributed, published or reproduced, in whole or in part. The information contained in this podcast does not constitute research or a recommendation from any Goldman Sachs entity to the listener. Neither Goldman Sachs nor any of its affiliates makes any representation or warranty, as to the accuracy or completeness of the statements or any information contained in this podcast and any liability therefor (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed. The views expressed in this podcast are not necessarily those of Goldman Sachs, and Goldman Sachs is not providing any financial, economic, legal, accounting or tax advice or recommendations in this podcast.  In addition, the receipt of this podcast by any listener is not to be taken as constituting the giving of investment advice by Goldman Sachs to that listener, nor to constitute such person a client of any Goldman Sachs entity.\n\n\nCopyright 2017 Goldman Sachs. All rights reserved.",
  "content:encoded": "<p>\n        \n        \n        \n        \n        \n        \n        \n        \n        \n        \n         Health care is projected to make up nearly forty percent of the US federal budget by 2025. In an effort to slow down cost increases, some in the industry have begun to explore value-based contracts, potentially transforming the industry's economics. Jami Rubin and Robert P. Jones of Goldman Sachs Research discuss how placing an emphasis on patient outcomes - instead of volumes of medications or services sold - could impact investors, companies and consumers.\n</p><p>\nThis podcast was recorded on July 12, 2017.\n</p><p>\nAll price references and market forecasts correspond to the date of this recording.\n</p><p>\nThis podcast should not be copied, distributed, published or reproduced, in whole or in part. The information contained in this podcast does not constitute research or a recommendation from any Goldman Sachs entity to the listener. Neither Goldman Sachs nor any of its affiliates makes any representation or warranty, as to the accuracy or completeness of the statements or any information contained in this podcast and any liability therefor (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed. The views expressed in this podcast are not necessarily those of Goldman Sachs, and Goldman Sachs is not providing any financial, economic, legal, accounting or tax advice or recommendations in this podcast.  In addition, the receipt of this podcast by any listener is not to be taken as constituting the giving of investment advice by Goldman Sachs to that listener, nor to constitute such person a client of any Goldman Sachs entity.\n</p><p>\nCopyright 2017 Goldman Sachs. All rights reserved.\n\n            \n      \n      \n      \n      \n      \n      \n      \n      \n      \n      \n      </p>",
  "itunes:duration": 1796,
  "guid": "http://www.goldmansachs.com/s/podcast-exchanges/exchanges-episode-67.mp3",
  "enclosure": ""
}